Print

Head-to-Head Study Comparing Navidea Biopharmaceuticals (NEOP)’s AZD4694 to the Gold Standard for Imaging Beta Amyloid Protein Deposits Presented at Alzheimer's Association International Conference  
7/23/2012 10:20:30 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that clinical data from a head-to head study comparing its amyloid imaging candidate, AZD4694, to the benchmark amyloid imaging agent, 11C-PiB (PiB), was presented at the Alzheimer's Association International Conference – AAIC in Vancouver, Canada by Professor Christopher Rowe, MD, FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia.
//-->